News
Alzamend Neuro shares surged after dosing the first patient in its AL001 Phase II trial. This novel lithium formulation aims for improved brain delivery and fewer side effects. Get the data-driven ...
Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide.1 Rising cases has led to an uptick in new treatments moving through the clinical ...
Shares of Alzamend Neuro, Inc. (ALZN) soared 82% on Thursday afternoon after the company announced the dosing of the first patient in its first Phase II clinical study of AL001 in healthy human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback